Wright agreed to pay $380 million in cash, stock and milestone payments to pick up BioMimetic and its Augment bone graft back in 2013. The FDA cleared the bone graft with indications as an alternative autograft for ankle and hindfoot fusion procedures in September 2015.
The Amsterdam-based company said that the agreement, dated March 1, 2013 between it and American Stock Transfer & Trust, is terminated effective March 1, according to a press release.
The Augment bone graft uses a combination of a bone-growth stimulator called recombinant human platelet-derived growth factor and beta-tricalcium phosphate, which is designed to form a scaffold for new bone growth.
Last June, Wright Medical won FDA premarket approval for an injectable version of the Augment bone graft.
DeviceTalks Minnesota's leadership track is designed to provide attendees with insights on topics such as:
Use code SAVE15 to save 15%!